title: Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix.
abstract: BACKGROUND
  Tumor vaccines show promise as a new approach for treating cancer. We have developed a murine prostate cancer cell line which can be used to study growth factor and extracellular matrix regulation of prostate differentiation and will be useful for generating tumor vaccines using the C3(1)/TAG transgenic model of prostate cancer.
  
  
  METHODS
  Pr-14 cells were established in defined growth media (GM) and grown in GM, GM + 2% fetal bovine serum (FBS) or DMEM + 10% FBS on plastic, collagen, or Matrigel. Immunofluorescence and Western blot analyses were performed using antibodies to cytokeratin, vimentin, SV40 large T-antigen, and androgen receptor (AR).
  
  
  RESULTS
  Pr-14 cells are cytokeratin-positive, vimentin-negative, and express SV40 large T-antigen. These cells are tumorigenic when injected into athymic nude mice and appear to be androgen-independent. Pr-14 cell lines are nontumorigenic when injected into syngeneic FVB/N mice, but form tumors in transgenic TAG-expressing FVB/N mice. Cell growth and morphology are dependent on media composition which determines whether ductal or acinar structures form when grown on Matrigel.
  
  
  CONCLUSIONS
  The mouse prostate adenocarcinoma cell line, Pr-14, undergoes alterations in the state of differentiation dependent upon serum concentration when grown on Matrigel. The Pr-14 cell line is a useful reagent to study prostate cell/extracellular matrix interactions, and for immunotherapy and cancer vaccine studies in C3(1)/TAG transgenic mice.
authors.affiliation: Laboratory of Chemoprevention, National Cancer Institute, Bethesda, Maryland 20892, USA.
authors.forename: C L
authors.initials: CL
authors.lastname: Jorcyk
authors.forename: M L
authors.initials: ML
authors.lastname: Liu
authors.forename: M A
authors.initials: MA
authors.lastname: Shibata
authors.forename: I G
authors.initials: IG
authors.lastname: Maroulakou
authors.forename: K L
authors.initials: KL
authors.lastname: Komschlies
authors.forename: M J
authors.initials: MJ
authors.lastname: McPhaul
authors.forename: J H
authors.initials: JH
authors.lastname: Resau
authors.forename: J E
authors.initials: JE
authors.lastname: Green
mesh_terms: D016475:3T3 Cells; D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D000818:Animals; D000952:Antigens, Polyomavirus Transforming / Q000378:metabolism; D015153:Blotting, Western; D002455:Cell Division / Q000187:drug effects; D003094:Collagen / Q000494:pharmacology; D003470:Culture Media; D004338:Drug Combinations; D005109:Extracellular Matrix; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006183:H-2 Antigens / Q000096:biosynthesis; D007621:Karyotyping; D007797:Laminin / Q000494:pharmacology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008822:Mice, Transgenic; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D011509:Proteoglycans / Q000494:pharmacology; D011944:Receptors, Androgen / Q000378:metabolism; D013194:Staining and Labeling; D014407:Tumor Cells, Cultured
chemical_list: D000952:Antigens, Polyomavirus Transforming; D003470:Culture Media; D004338:Drug Combinations; D006183:H-2 Antigens; D007797:Laminin; D011509:Proteoglycans; D011944:Receptors, Androgen; C059485:matrigel; D003094:Collagen